Join our community of smart investors

Is AstraZeneca a victim of vaccine nationalism?

AstraZeneca/Oxford vaccine makers could be forgiven a persecution complex as Europe’s regulators pause the roll-out to investigate blood clots
Is AstraZeneca a victim of vaccine nationalism?
  • Several European countries have paused the roll-out of the AstraZeneca/Oxford vaccine on concerns over elevated levels of blood clotting
  • 11m AstraZeneca/Oxford vaccine doses have been administered in the UK, with only 40 embolism cases recorded

An investigation into the cause of blood clots has led several of Europe’s medicines regulators to pause the roll-out of the AstraZeneca/Oxford vaccine after cases came to light in Norway, Ireland and Germany. Regulators will meet to discuss the significance of these cases in the context of a programme that has seen 17m Oxford jabs administered so far, 11m of those in the UK alone.

The questions for pharmaceutical market watchers are whether there is any real scientific basis for worries about the vaccine, whether it is just another example of creeping ‘vaccine nationalism’ and whether it will have any conceivable commercial impact on AstraZeneca?

To continue reading...
Join our Community of Smart Investors
  • Independent full-length company analysis
  • Actionable investment ideas and recommendations
  • Expert investment tools and data
  • Stock screens from Algy Hall
Have an account? Sign in